Printer Friendly

BELMAC REPORTS RESULTS FOR FISCAL YEAR ENDED JUNE 30, 1992

 BELMAC REPORTS RESULTS FOR FISCAL YEAR ENDED JUNE 30, 1992
 TAMPA, Fla., Sept. 9 /PRNewswire/ -- Belmac Corporation (AMEX: BLM) announced today results of operations for its fiscal year ended June 30, 1992.
 BELMAC CORPORATION
 (Dollars in Thousands)
 FYE 6/30/92 FYE 6/30/91
 Sales $ 13,138 $ --
 Cost of Sales 8,871 --
 S, G and A Expenses 8,665 1,596
 Research and Development 5,168 764
 Depreciation and Amortization 925 146
 Net Income (Loss) $ (10,811) $ (2,476)
 Net Income (Loss) per share $ (1.11) $ (.36)
 Average Shares Outstanding 9,969,519 6,949,497
 The loss for 1992 was attributable to investments in research and development ($5,168,000) and the launch of Biolid in France ($5,983,000).
 The introduction of Biolid, Belmac's new macrolide antibiotic, has resulted in a market share in excess of 4 percent after only three months of marketing and a high rating for brand name recognition. Biolid is already ranked number 6 in sales volume out of 17 similar antibiotics on the French market. The company's management remains confident that its initial investment in marketing Biolid will lead to significant profits.
 The company's investment in research and development has led to significant progress in the development of five new products. Belmac expects to file five INDs with the United States FDA in fiscal year 1993. The company will release a more detailed update regarding its research and development activities on Thursday, Sept. 10.
 "Other highlights of 1992 include pre-tax profits of Chimos (our French professional products subsidiary) of approximately $958,000 and the establishment of two very effective sales organizations in France and Spain," said Belmac's chief executive officer, Jean-Francois Rossignol. "A weak dollar and slower than expected sales of Amodex (our brand of Amoxicillin) in France contributed to a higher than expected loss for the fourth quarter. All in all, we achieved our objectives in 1992, and we are well positioned for 1993," added Rossignol.
 Belmac Corporation is an emerging pharmaceutical company focusing on the development and marketing of drugs for the treatment of infectious and parasitic diseases.
 -0- 9/9/92
 /CONTACT: Marc S. Ayers, chief financial officer of Belmac Corporation, 813-286-4401/
 (BLM) CO: Belmac Corporation ST: Florida IN: MTC SU: ERN


JB-AW -- FL010 -- 7463 09/09/92 11:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1992
Words:382
Previous Article:COMSTOCK RESOURCES CLOSES ACQUISITION OF OIL & GAS PROPERTY
Next Article:HADSON ANNOUNCES ADDITIONAL MODIFICATIONS TO ITS PURPOSED PLAN OF REORGANIZATION
Topics:


Related Articles
BELMAC ANNOUNCES REVENUES FOR FIRST QUARTER
BELMAC ANNOUNCES SECOND QUARTER RESULTS
BELMAC REPORTS FIRST QUARTER RESULTS
BELMAC TERMINATES ACQUISITION DISCUSSIONS WITH TWO EUROPEAN DRUG COMPANIES AND REPORTS RESULTS FOR QUARTER ENDED DEC. 31, 1992
BELMAC SEES SHARPLY IMPROVING FIRST QUARTER OPERATING RESULTS
BELMAC REPORTS RECORD SALES FOR FIRST QUARTER 1993
BELMAC CORPORATION REPORTS SUBSTANTIAL IMPROVEMENT FOR SECOND QUARTER
BELMAC CORPORATION ANNOUNCES RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 1993
BELMAC'S IMPROVED FINANCIAL PERFORMANCE REFLECTS COST-CUTTING, NEW MARKETING INITIATIVES
BELMAC REPORTS 16% INCREASE IN REVENUES FOR SECOND QUARTER OF 1995

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters